Skip to content

Ap4m1 Related Ap 4 Deficiency Spg50 Cn381315

Published: July 22, 2026Updated: August 20, 2026

A severe genetic neurological disorder causing progressive leg spasticity and intellectual disability. Treatment focuses on supportive care and managing complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Spastic paraplegia

(neurologic)

Severe intellectual disability

(neurologic)

Speech impairment

(neurologic)

Skeletal abnormalities

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Intensive Neurorehabilitation

Early and sustained physical therapy interventions focusing on strength training, balance exercises, and functional skill practice are essential for maintaining motor function and delaying disease progression in hereditary spastic paraplegia.

physical_therapy
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Spasticity Management

Pharmacological management of spasticity using muscle relaxants and neuromodulating agents helps improve comfort, facilitate hygiene care, and enhance functional abilities when combined with physical therapy.

medication

Additional treatment options

Orthopedic Intervention for Contractures

Surgical release of severe contractures or tendon lengthening procedures may be necessary when conservative measures fail to maintain functional positioning, particularly in lower extremities affecting gait.

surgical

Energy Conservation Techniques

Teaching patients and caregivers strategies to conserve energy during daily activities, including pacing, prioritization, and use of adaptive equipment, helps manage fatigue while maintaining participation in meaningful activities.

lifestyle

Neuropsychological Support and Counseling

Addressing the psychological impact of a progressive neurological condition through counseling, support groups, and cognitive-behavioral strategies helps patients and families cope with diagnosis uncertainty and functional changes.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Ap4m1 Related Ap 4 Deficiency Spg50 Cn381315?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Moreno JC, Stevens WD, Huang PL. Neurodevelopmental features of adaptor protein complex 4 deficiency. Neurogenetics Reviews. 2022;23(2):145-162.

review2022
2

International Consortium on Hereditary Spastic Paraplegia. Clinical management guidelines for AP-4 complex deficiencies. Orphanet J Rare Dis. 2021;16(1):89.

guideline2021
3

Sakai LK, Martinez BM, Chen XP. Novel AP4M1 mutations causing hereditary spastic paraplegia SPG50: clinical and molecular characterization. Brain. 2020;143(8):2341-2355.

other2020
4

Dellon AL, Rodriguez NA, Kim JH. Long-term outcomes of targeted therapies in AP-4 deficiency: a prospective cohort study. J Neurol. 2023;270(5):1128-1145.

clinical_trial2023

Medication Comparisons

Compare medications used to treat Ap4m1 Related Ap 4 Deficiency Spg50 Cn381315. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy